Literature DB >> 31342326

Vitamin K Antagonist Use and Fracture.

Wallis C Y Lau1,2, Kenneth K C Man3,4, Ian C K Wong3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31342326      PMCID： PMC6957648          DOI： 10.1007/s11606-019-05185-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  5 in total

1.  A Systematic Review and Meta-analysis of the Association Between Vitamin K Antagonist Use and Fracture.

Authors:  Wendy Fiordellisi; Katherine White; Marin Schweizer
Journal:  J Gen Intern Med       Date:  2018-12-03       Impact factor: 5.128

2.  Risk of bone fractures among users of oral anticoagulants: An administrative database cohort study.

Authors:  Ersilia Lucenteforte; Alessandra Bettiol; Niccolò Lombardi; Alessandro Mugelli; Alfredo Vannacci
Journal:  Eur J Intern Med       Date:  2017-07-19       Impact factor: 4.487

3.  Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.

Authors:  Jan Steffel; Robert P Giugliano; Eugene Braunwald; Sabina A Murphy; Michele Mercuri; Youngsook Choi; Phil Aylward; Harvey White; Jose Luis Zamorano; Elliott M Antman; Christian T Ruff
Journal:  J Am Coll Cardiol       Date:  2016-09-13       Impact factor: 24.094

4.  Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation.

Authors:  Wallis C Y Lau; Esther W Chan; Ching-Lung Cheung; Chor Wing Sing; Kenneth K C Man; Gregory Y H Lip; Chung-Wah Siu; Joanne K Y Lam; Alan C H Lee; Ian C K Wong
Journal:  JAMA       Date:  2017-03-21       Impact factor: 56.272

5.  Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.

Authors:  Faye L Norby; Lindsay G S Bengtson; Pamela L Lutsey; Lin Y Chen; Richard F MacLehose; Alanna M Chamberlain; Ian Rapson; Alvaro Alonso
Journal:  BMC Cardiovasc Disord       Date:  2017-09-06       Impact factor: 2.298
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.